Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive data from new trial of CSU therapy Xolair

Novartis reports positive data from new trial of CSU therapy Xolair

12th June 2015

Novartis has announced new analyses from pivotal Phase III registration studies showing the quality of life benefits associated with its chronic spontaneous urticaria (CSU) therapy Xolair.

Previous analyses of the data from these phase III studies – ASTERIA I, ASTERIA II and GLACIAL – Xolair was found to be highly effective in either reducing or eliminating CSU symptoms in patients for whom previous therapies had failed.

The new post-hoc analyses presented at the World Congress of Dermatology revealed that patients treated with Xolair for 12 weeks experienced improvements of 78 per cent in terms of quality of life scores.

It was also indicated that if left untreated, CSU can have a consistent negative impact on quality of life among patients.

Vasant Narasimhan, global head of development at Novartis Pharmaceuticals, said: "These results confirm that Xolair, in addition to improving the symptoms of CSU, effectively improves the quality of life in patients affected by this unpredictable and painful disease."

Xolair was approved for NHS use by the National Institute of Health and Care Excellence as an add-on therapy option for severe CSU in adults and young people earlier this month.ADNFCR-8000103-ID-801790899-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.